Contact Lenses Price  
Contact Lenses Search:
Contact Lenses Contact Lens Rebates All Discount Contacts
Product Type
1-2 Week Disposable
Bifocal Contact Lenses
Color Contact Lenses
Daily Disposable Contacts
Monthly Disposable
Rigid Gas Permeables
Toric Contact Lenses
Vial Contact Lenses
Halloween Contact Lenses/ Special Effects Contacts
 
Manufacturers
Bausch & Lomb
CIBA Vision
Coopervision
Johnson & Johnson
Ocular Sciences
Wesley-Jessen
Independent labs
LifeStyle Company
Paragon Vision Sciences
Soft Lens Technology
OSI/American Hydron
RGP
Hydrogel Vision Corporation
Optical Polymer Research

Ocular Sciences

 

Since Ocular Sciences was incorporated in 1985, its strategy has been to market high quality soft contact lenses to eye care professionals at competitive prices using a low cost to serve operating structure. The company sells products marketed for reusable and disposable wearing regimens. The company sells its products exclusively to eye care professionals because soft contact lenses are medical devices and as such the company believes wearers should return to their original prescribing eye care professional for on going follow up care.

Ocular Sciences' corporate headquarters are located in Concord, California. The Company has approximately 4,000 employees worldwide.

Go to Ocular Sciences website


Please choose the following products of Ocular Sciences

Aqualens 55 Aqualens 55
Biomedics 38 Biomedics 38
Biomedics 55 Biomedics 55
Biomedics 55 Premier - Ultraflex 55 Premier Biomedics 55 Premier - Ultraflex 55 Premier
Biomedics One Day 90 Pack Biomedics One Day 90 Pack
Biomedics Toric(UltraFlex Toric) Biomedics Toric(UltraFlex Toric)
Edge III ProActive Edge III ProActive
Edge III ProActive XT Edge III ProActive XT
Hydrogenics 60 Hydrogenics 60
Proactive 55 Proactive 55
Page:1 2 

Today's News about Ocular Sciences


Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®
ATLANTA, May 7, 2013 /PRNewswire/-- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...

Alimera Sciences Reports First Quarter 2013 Financial Results
ATLANTA, May 9, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...

Ophthalmic Drugs: World Market Prospects 2013-2023
NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Ophthalmic Drugs: World Market Prospects 2013-2023 http://www.reportlinker.com/p0847305/Ophthalmic-Drugs-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ...

Alimera Sciences Announces New PDUFA Date For ILUVIEN®
ATLANTA, May 1, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...

pSivida Corp. Announces Commercial Launch of ILUVIEN® in Germany with First Patient Treated
pSivida Corp. , a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that ILUVIEN®, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema , is now commercially available in Germany.

Alimera Sciences Announces ILUVIEN® Now Available In U.K.
      ATLANTA, April 29, 2013 /PRNewswire/ -- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ...

Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
ATLANTA, May 3, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ...

pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013
pSivida Corp. , a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the U.S. Food and Drug Administration acknowledged receipt of the resubmission of the New Drug Application for ILUVIEN® for treatment of chronic diabetic macular edema and stated that the resubmission was considered a complete, class 2 response to the ...

Alimera Sciences Secures $20 Million Debt Facility
ATLANTA, May 8, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...

Perelman School of Medicine at the University of Pennsylvania Names First Vice Dean for Diversity and Inclusion, Eve J ...
Prior to joining Penn Medicine, Dr. Higginbotham held numerous academic leadership roles, including Senior Vice President and Executive Dean for Health Sciences at Howard University and Dean and Senior Vice President for Academic Affairs at Morehouse School of Medicine in Atlanta.
 
© 2004-2011 ContactLensesPrice.com All rights reserved.
Contact Us Privacy Policy Term of Use Resources